Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of FSME-IMMUN NEW in Children and Adolescents
NCT00161863Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2002
- Modality
- Whole Inactivated Vaccines
- Countries
- 3
01
Overview
A Phase 3 trial of FSME-IMMUN in tick-borne encephalitis (TBE), sponsored by Pfizer. Started Sep 2002; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on NCT00161863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161863.